Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
398 Index<br />
±, tumor cell killing<br />
cross-priming<br />
220<br />
±, CpG DNA 276<br />
±, dendritic cells 181<br />
±, HSPs 255<br />
cross-reaction, with autoantigens 215<br />
CRs see chimeric receptors<br />
CTantigens 21, 26f.<br />
CT26 colon carcinoma cells 314±318<br />
CTL see cytotoxic T lymphocytes<br />
CTL epitopes 32, 34±37<br />
±, identification 41±44<br />
±, monitoring 44±49<br />
±, tumor-immune system interaction<br />
66<br />
CTL precursor (pCTL)<br />
CTL responses<br />
317<br />
±, effects of IL-10 127<br />
±, inhibition <strong>by</strong> MIF 130<br />
±, low-affinity 194<br />
±, MHC class I alterations 77f.<br />
±, mucins 135<br />
±, tumor site 46±49<br />
cyclophosphamide, suppression of IL-10<br />
129<br />
cytochrom P450 11<br />
cytokine gene therapy 327<br />
cytokine-producing cells, flow cytometry<br />
detection 195<br />
cytokine receptor family II (CRF2)<br />
cytokines<br />
156<br />
±, bacterial immunotherapy 274<br />
±, DCs 105<br />
±, effects of dendritic cells 181<br />
±, hybrid cell vaccination (HCV) 234<br />
±, IL-2, IL-10 100<br />
±, immunoinhibitory factors 109<br />
±, in cancer immune therapy 311±346<br />
±, interferon (IFN)-g 31<br />
±, macrophages 108<br />
±, NK cells 102ff.<br />
cytolysis, hTERT specific 9 f.<br />
cytomegalovirus (CMV), BMT 305f.<br />
cytotoxic epitopes, dendritic cells<br />
cytotoxic T lymphocytes (CTL)<br />
187<br />
±, CD8 +<br />
3, 6, 8 ff., 41<br />
±, GvHD 303<br />
±, HCV 234<br />
±, T-body approach 292<br />
±, see also CTL responses<br />
d<br />
damage, cell 367<br />
danger signal<br />
±, definition 224<br />
±, dendritic cells 181<br />
±, immunocytokines 324f.<br />
±, tumor cell killing 218<br />
±, tumor microenvironment 96f.<br />
databases, SEREX antigens 25<br />
DC counts, in cancer patients 183<br />
DC immunotherapy 195ff.<br />
DC mobilization, in cancer patients 183<br />
DCs see dendritic cells<br />
delayed-type hypersensitivity (DTH) 188<br />
DNGER see low-affinity receptor for the nerve<br />
growth factor<br />
dendritic cells (DCs)<br />
±, <strong>and</strong> cancer 179±203<br />
±, antigen presentation 210<br />
±, effects of IL-10 128, 158f.<br />
±, effects of TGF-b 123f.<br />
±, gp96 262f.<br />
±, HCV 234±241<br />
±, HSPs 254<br />
±, immunocytokines 322ff., 329<br />
±, tumor cell killing 218<br />
±, tumor microenvironment 105ff.<br />
dendritic-like cells, immunocytokines 320<br />
deoxyspergualin 367<br />
DFMO see difluoromethyornithine<br />
diabodies 364<br />
differentiation antigens 21, 231<br />
difluoromethyornithine (DFMO) 133<br />
diphteria toxin (DT) 350±361<br />
disease, autoimmune 209, 211, 215f.<br />
disialoganglioside (GD 2)<br />
±, antibody 312f., 341<br />
±, immunocytokines 330ff.<br />
display technology, immunotoxins<br />
363±366<br />
disulfide-stabilized Fvs (dsFvs) 355ff.,<br />
360f.<br />
DLI see donor lymphocyte infusion<br />
DNA, bacterial 268±271<br />
DNA backbone, ODN classes 272ff.<br />
DNA-based immunotoxins 351±357<br />
DNA hot spots 366<br />
DNA vaccine, CEA-based 321±327<br />
donor lymphocyte infusions (DLIs) 275,<br />
301±307<br />
dose-limiting toxicity, immunotoxins 367f.<br />
down regulation, MHC class I 69±76<br />
drugs, suppression of IL-10 129<br />
dsFvs see disulfide-stabilized Fvs<br />
DT see diphteria toxin<br />
DTH see delayed-type hypersensitivity<br />
dysfunction, immune cells in cancer 108f.
Change language